Daily Self-Monitoring and Feedback of Circadian Rhythm Measures in Major Depression and Bipolar Disorder Using Wearable Devices and Smartphones-The Circadian Rhythm for Mood (CRM®) Trial Protocol: A Randomized Sham Controlled Double-Blind Trial

被引:0
|
作者
Yeom, Ji Won [1 ,2 ]
Yoon, Yeaseul [1 ,2 ]
Seo, Ju Yeon [1 ,2 ]
Cho, Chul-Hyun [1 ,2 ]
Lee, Taek [3 ]
Lee, Jung-Been [3 ]
Jeon, Sehyun [4 ]
Kim, Leen [1 ,2 ]
Lee, Heon-Jeong [1 ,2 ]
机构
[1] Korea Univ, Anam Hosp, Coll Med, Dept Psychiat, 73 Goryeodae Ro, Seoul 02841, South Korea
[2] Korea Univ, Chronobiol Inst, Seoul, South Korea
[3] Sun Moon Univ, Coll Software & Convergence, Div Comp Sci & Engn, Asan, South Korea
[4] Samsung Sleep & Mind Clin, Seoul, South Korea
关键词
Mood disorders; Digital therapeutic; Circadian rhythms; Clinical trial; I DISORDER; SCALE; EPIDEMIOLOGY; VALIDATION; INVENTORY; VALIDITY; LITHIUM; MANIA;
D O I
10.30773/pi.2024.0133
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The circadian rhythm for mood (CRM) is a digital therapeutic, which aims to prevent mood episode and improve clinical course in patients with major mood disorders. Developed on the circadian rhythm hypothesis of mood disorder, CRM predicts the impending risk of mood episode with its built-in algorithm, utilizing wearable devices data and daily self-reports, and provides personalized feedback. In a pilot study of the CRM, the users experienced less frequent and shorter duration of mood episodes than the non-users. To investigate the efficacy of the upgraded CRM, a double-blind, randomized, sham-controlled, parallel-group trial is designed. Patients aged between 19 and 70, diagnosed with bipolar I disorder, bipolar II disorder, or major depressive disorder, in a euthymic state for more than two months, can participate. During this 12-month trial, participants are assessed for episode recurrence every three months, and the efficacy of the CRM as a potential digital therapeutic is evaluated.
引用
收藏
页码:918 / 924
页数:7
相关论文
共 2 条
  • [1] Daily electronic self-monitoring in bipolar disorder using smartphones - the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial
    Faurholt-Jepsen, M.
    Frost, M.
    Ritz, C.
    Christensen, E. M.
    Jacoby, A. S.
    Mikkelsen, R. L.
    Knorr, U.
    Bardram, J. E.
    Vinberg, M.
    Kessing, L. V.
    PSYCHOLOGICAL MEDICINE, 2015, 45 (13) : 2691 - 2704
  • [2] Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones-the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial
    Faurholt-Jepsen, Maria
    Vinberg, Maj
    Frost, Mads
    Christensen, Ellen Margrethe
    Bardram, Jakob
    Kessing, Lars Vedel
    BMC PSYCHIATRY, 2014, 14